Claims

1. A composition comprising at least one bacterial strain comprising bile acid deconjugation activity and/or 7-epimerization activity, for use in treating or reducing the risk of intrahepatic cholestasis of pregnancy in a subject.

2. The composition for use of claim 1, wherein said use comprises treating or reducing the risk of pruritis in the subject.

3. The composition for use of any one of claims 1 to 2, wherein said composition comprises at least two bacterial strains, wherein said bacterial strains together comprise bile acid deconjugation activity and 7-epimerization activity and; wherein the first bacterial strain comprises bile acid deconjugation activity and a second bacterial strain comprises 7-epimerization activity.

4. The composition for use of any one of claims 1 to 3, wherein said composition comprises at least three bacterial strains, wherein said bacterial strains together comprise bile acid deconjugation activity and 7-epimerization activity; and wherein the first bacterial strain comprises bile acid deconjugation activity, a second bacterial strain comprises 7α-hydroxysteroid dehydrogenase (HSDH) activity, and a third bacterial strain comprising 7β-HSDH activity.

5. The composition for use of any one of claims 1 to 4, wherein the composition further comprises at least one bacterial strain comprising sulfate reducing activity.

6. The composition for use of any one of the preceding claims, wherein the bacterial strain comprising the bile acid deconjugation activity is *Bifidobacterium longum* ATCC BAA-999.

7. The composition for use of any one of claims 1 6, wherein the bacterial strain comprising 7-epimerization activity is *Clostridium baratii* ATCC 27638.

8. The composition for use of claim 4, wherein the bacterial strain comprising 7α-HSDH activity is *Bacteroides fragilis* ATCC 25285 and/or *Bacteroides thetaiotaomicron* DSM 2079.

9. The composition for use of claim 4, wherein the bacterial strain comprising 7β-HSDH activity is *Collinsella aerofaciens* ATCC 25986.

10. The composition for use of claim 4, wherein the bacterial strain comprising sulfate reducing activity is *Desulfovibrio piger* DSM 32187.

11. The composition for use of claims 1 or 4, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, and *Collinsella aerofaciens* ATCC 25986.

12. The composition for use of claims 1 or 4, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, and *Collinsella aerofaciens* ATCC 25986.

13. The composition for use of any one of claims 1 to 3, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999 and *Clostridium baratii* ATCC 27638.

14. The composition for use of any one of claims 1 or 5, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, *Collinsella aerofaciens* ATCC 25986, and *Desulfovibrio piger* DSM 32187.

15. The composition for use of any one of claims 1 or 5, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, *Collinsella aerofaciens* ATCC 25986 and *Desulfovibrio piger* DSM 32187.

16. The composition for use of any one of claims 1 or 5, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Clostridium baratii* ATCC 27638 and *Desulfovibrio piger* DSM 32187.

17. The composition for use of any of the preceding claims, wherein said use further comprises a prebiotic.

18. The composition for use of claim 17, wherein the prebiotic is inulin.

19. The composition for use of any of the preceding claims, wherein the subject is a mammal.

20. The composition for use of claim 19, wherein the subject is a human.

21. A medicament for use in treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial strain comprising bile acid deconjugation activity and/or 7-epimerization activity, thereby treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof.

22. The medicament of claim 21, wherein said composition or intrahepatic cholestasis or subject is as defined in any one of claims 2 to 20.

23. The medicament of claim 21, wherein the composition further comprises at least one bacterial strain comprising sulfate reducing activity.